Because of this strong proinflammatory activity, therapeutic interventions have recently focused on neutralizing antibodies against C5a and C5aR as potential candidates for the treatment of severe inflammatory conditions, such as bacterial-induced sepsis (26, 27). The gene discussed is C5AR1; the disease is Sepsis.